NCT04294498View on ClinicalTrials.gov

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2026

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Durvalumab

Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

collaborator

AstraZeneca

INDUSTRY

lead

National Taiwan University Hospital

OTHER